Document is current
Any future updates will be listed below
-
Authors
Tolosa, Eduardo https://orcid.org/0000-0002-3781-0854
Poewe, Werner https://orcid.org/0000-0003-4367-0971
Noyce, Alastair J.
Svenningsson, Per https://orcid.org/0000-0001-6727-3802
Mahlknecht, Philipp
Marti, Maria Jose
- License Information
-
More Information
Article History
Accepted: 15 January 2026
First Online: 13 February 2026
Competing interests
: E.T. reports honoraria for consultancy from Prevail/Lilly and has received funding for research from the Michael J Fox Foundation. Unrelated to this work, W.P. has received personal lecture fees and/or consultancy fees from Alterity, AbbVie, AC Immune, BIAL, Boehringer, Britannia, Lilly, Lundbeck, Merck, Merz Pharma, Mitsubishi-Tanabe, Neuroderm, Novo Nordisk, Roche, Sanofi, Sumitomo, Takeda, Teva, UCB and Zambon, and has received grant support from the Michael J Fox Foundation and the European Union programmes FP7 and Horizon, and has received royalties from Cambridge University Press, Oxford University Press, Thieme and Wiley Blackwell. A.J.N. is supported by the Michael J Fox Foundation and reports honoraria from Teva and travel and meeting expenses from the International Movement Disorders Society. P.S. has received honoraria for lectures or courses from Abbvie, Britannia, Lundbeck, Merz Therapeutics and Zambon, owns stock in Bioarctic and Irlab, and has received major research grants from Aligning Science Across Parkinson’s, the Knut and Alice Wallenberg Foundation, the Michael J Fox Foundation and the Swedish Research Council. M.J.M. has received grant support from the Michael J Fox Foundation and honoraria for consultancy from Bial. P.M. declares no competing interests.
